La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Estrella Immunopharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Estrella Immunopharma..

Estrella Immunopharma (NASDAQ:ESLA) Azioni, Catena delle Opzioni

Estrella Immunopharma

Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma Inc

WIIM

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health shares are trading higher. Strength has been attributed to President-elect Donald Trump's plans to nominate Marty Makary to lead the FDA.

Investors with a lot of money to spend have taken a bearish stance on Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with UBER, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 39 uncommon options trades for Uber Technologies.
This isn't normal.
The overall sentiment of these big-money traders is split between 41% bullish and 53%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $316,232, and 34 are calls, for a total amount of $2,204,315.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $100.0 for Uber Technologies during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Uber Technologies's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Uber Technologies's whale trades within a strike price range from $50.0 to $100.0 in the last 30 days. 
<h3>Uber Technologies Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732563026_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UBER</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$10.95</td>
<td>$10.85</td>
<td>$10.87</td>
<td>$95.00</td>
<td>$243.8K</td>
<td>635</td>
<td>1.0K</td>
</tr>
<tr>
<td>UBER</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$12.6</td>
<td>$12.3</td>
<td>$12.3</td>
<td>$75.00</td>
<td>$228.9K</td>
<td>3.1K</td>
<td>265</td>
</tr>
<tr>
<td>UBER</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$16.05</td>
<td>$14.65</td>
<td>$15.69</td>
<td>$80.00</td>
<td>$156.9K</td>
<td>343</td>
<td>101</td>
</tr>
<tr>
<td>UBER</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$15.7</td>
<td>$15.4</td>
<td>$15.64</td>
<td>$80.00</td>
<td>$156.4K</td>
<td>343</td>
<td>301</td>
</tr>
<tr>
<td>UBER</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$15.95</td>
<td>$15.4</td>
<td>$15.63</td>
<td>$80.00</td>
<td>$156.3K</td>
<td>343</td>
<td>201</td>
</tr>
</tbody>
</table>

<h3>About Uber Technologies</h3>
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides "aerial ride-sharing." Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 150 million users who order rides or food at least once a month.
<h3>Current Position of Uber Technologies</h3>
<ul>
<li>With a volume of 8,625,720, the price of UBER is up 2.51% at $73.31. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 72 days.</li>
</ul>
<h3>What The Experts Say On Uber Technologies</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $93.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Uber Technologies with a target price of $90. 
&#x2A; An analyst from Loop Capital has decided to maintain their Buy rating on Uber Technologies, which currently sits at a price target of $86. 
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on Uber Technologies, which currently sits at a price target of $85. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Uber Technologies, targeting a price of $120. 
&#x2A; An analyst from Gordon Haskett upgraded its action to Buy with a price target of $85. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Uber Technologies, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

UBER

Market Whales and Their Recent Bets on UBER Options

Investors with a lot of money to spend have taken a bullish stance on Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NEM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Newmont.
This isn't normal.
The overall sentiment of these big-money traders is split between 70% bullish and 20%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $203,670, and 6 are calls, for a total amount of $800,199.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $30.0 and $60.0 for Newmont, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Newmont options trades today is 3564.38 with a total volume of 5,631.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Newmont's big money trades within a strike price range of $30.0 to $60.0 over the last 30 days.
<h3>Newmont Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732563021_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.25</td>
<td>$3.15</td>
<td>$3.24</td>
<td>$45.00</td>
<td>$324.0K</td>
<td>1.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.5</td>
<td>$7.35</td>
<td>$7.5</td>
<td>$40.00</td>
<td>$269.9K</td>
<td>4.4K</td>
<td>440</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.8</td>
<td>$1.75</td>
<td>$1.8</td>
<td>$42.50</td>
<td>$90.0K</td>
<td>15.2K</td>
<td>944</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.1</td>
<td>$0.92</td>
<td>$1.1</td>
<td>$37.50</td>
<td>$84.7K</td>
<td>5.5K</td>
<td>772</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$11.1</td>
<td>$9.9</td>
<td>$11.05</td>
<td>$37.50</td>
<td>$56.1K</td>
<td>130</td>
<td>51</td>
</tr>
</tbody>
</table>

<h3>About Newmont</h3>
Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 5.5 million ounces of gold in 2024 from its core mines and 6.8 million in total. It is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2023.
<h3>Where Is Newmont Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 5,909,976, with NEM's price down by -2.87%, positioned at $42.13.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 87 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Newmont with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Newmont's Options Frenzy: What You Need to Know

Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) revealed 19 unusual trades.
Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued at $321,410.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $220.0 and $280.0 for Alnylam Pharmaceuticals, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Alnylam Pharmaceuticals stands at 355.17, with a total volume reaching 1,362.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Alnylam Pharmaceuticals, situated within the strike price corridor from $220.0 to $280.0, throughout the last 30 days.
<h3>Alnylam Pharmaceuticals 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732563016_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$38.0</td>
<td>$35.6</td>
<td>$38.0</td>
<td>$220.00</td>
<td>$190.0K</td>
<td align="right">262</td>
<td align="right">50</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$20.9</td>
<td>$18.5</td>
<td>$19.0</td>
<td>$270.00</td>
<td>$127.3K</td>
<td align="right">601</td>
<td align="right">250</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$28.0</td>
<td>$26.9</td>
<td>$28.0</td>
<td>$280.00</td>
<td>$120.4K</td>
<td align="right">312</td>
<td align="right">250</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$28.3</td>
<td>$25.2</td>
<td>$28.3</td>
<td>$280.00</td>
<td>$107.5K</td>
<td align="right">312</td>
<td align="right">250</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$27.5</td>
<td>$27.4</td>
<td>$27.5</td>
<td>$280.00</td>
<td>$82.5K</td>
<td align="right">312</td>
<td align="right">250</td>
</tr>
</tbody>
</table>

<h3>About Alnylam Pharmaceuticals</h3>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
After a thorough review of the options trading surrounding Alnylam Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Alnylam Pharmaceuticals</h3>
<ul>
<li>With a volume of 460,809, the price of ALNY is up 3.96% at $254.59. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 80 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Alnylam Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ALNY

Check Out What Whales Are Doing With ALNY

The Benzinga Future of Digital Assets event featured a panel on NFTs and the metaverse, sparking discussions about their long-term potential despite current skepticism. Post panel, <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42138947/bitcoin-zeroes-in-on-100000-but-this-indicator-signals-one-more-brief-correction">Ian Horne, head of content </a>for Money20/20 Amsterdam, shared his perspective on how these technologies may evolve and gain broader acceptance over time.
<h1 class="wp-block-heading">Moving Beyond Skepticism</h1>
Horne acknowledged the criticism NFTs and the metaverse have faced in recent years, often due to unrealistic expectations and failed projects. But, he argued that their core concepts remain relevant for the future of digital interaction.
"These concepts have been derided rightly for failures in recent years," Horne said, "but long term, the idea of a metaverse becoming a thriving idea, and NFTs being important to identity and how we relate to others online, is completely still valid."
The panel conversation, which included Alex Salnikov of Rarible, delved into how practical applications of NFTs and metaverse technology could reshape online experiences. Horne emphasized that discussing these ideas in a grounded way helps audiences better understand their potential.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42138947/bitcoin-zeroes-in-on-100000-but-this-indicator-signals-one-more-brief-correction">Bitcoin Zeroes In On $100,000, But This Indicator Signals One More Brief Correction</a>
<h1 class="wp-block-heading">Adoption Through Integration</h1>
Addressing skepticism, Horne explained that widespread adoption of these technologies would likely happen when seamlessly integrated into daily activities without being labeled as NFTs or metaverse applications. 
"I think the real adoption of these things is going to happen when we don't talk about it like it being the metaverse or like it being an NFT," he said. Instead, users will engage with digital tools like tokens or online marketplaces without understanding the underlying technology.
Horne stressed the focus should shift to the value these technologies add rather than their technical definitions. "When we're talking about the value add and not the technology, that's when I think we're nailing it," he added.
The panel discussion at the event reflected a broader sentiment that while challenges remain, the long-term promise of NFTs and the metaverse lies in their ability to integrate seamlessly into the digital world and shape how individuals interact online.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42138209/microstrategy-trading-at-insane-256-premium-to-bitcoin-holdings-research-shows">MicroStrategy Trading At &#8216;Insane&#8217; 256% Premium To Bitcoin Holdings, Research Shows</a></li>
</ul>
Photo by Corynn Egreczky.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Interview

NFTs, Metaverse 'Derided Rightly,' But Experts See Bright Future Ahead

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 400 points on Monday.
The Dow traded up 0.95% to 44,718.05 while the NASDAQ rose 0.25% to 19,050.84. The S&amp;P 500 also rose, gaining, 0.29% to 5,986.39.
Check This Out: <a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1.6% on Monday.
In trading on Monday, energy shares fell by 1.8%.
Top Headline
The Dallas Fed&#8217;s Texas manufacturing activity index rose to -2.7 in November compared to a reading of -3 in the previous month and versus market estimates of -2.4.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>BridgeBio Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) shares shot up 19% to $27.80 after the company announced that the FDA approved Attruby to treat adults with ATTR-CM.</li>
<li>Shares of Quantum Computing Inc. &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) got a boost, surging 12% to $6.80 after AWS announced Quantum Embark program.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) shares were also up, gaining 56% to $2.7211 after the company completed a $100 million at-the-market equity offering, with plans to use the proceeds for working capital, capital expenditures, and advancements in superconducting quantum computing technology.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) shares dropped 81% to $4.7301 after the company announced Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer&#8217;s disease in the ReThink-ALZ Phase 3 study.</li>
<li>Shares of Oncternal Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCT#NASDAQ">ONCT</a>) were down 46% to $0.6201 after the company announced that NASDAQ plans to delist its stock.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) was down, falling 14% to $0.6205 after the company announced restructuring amidst its bankruptcy and delisting challenges.</li>
</ul>
Commodities In commodity news, oil traded down 3.3% to $68.92 while gold traded down 3.4% at $2,621.10.
Silver traded down 3.4% to $30.265 on Monday, while copper rose 0.2% to $4.0925.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.06%, Germany's DAX gained 0.43% and France's CAC 40 rose 0.03%. Spain's IBEX 35 Index rose 0.47%, while London's FTSE 100 gained 0.36%.
The Ifo Business Climate indicator for Germany fell to 85.7 in November compared to 86.5 in October and down from market expectations of 86. Producer prices in Spain fell by 3.9% year-over-year in October.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 gaining 1.30%, Hong Kong's Hang Seng Index falling 0.41%, China's Shanghai Composite Index falling 0.11% and India's BSE Sensex gaining 1.25%.
Economics
<ul>
<li>The Chicago Fed National Activity Index fell to -0.40 in October compared to -0.27 in the previous month and versus market estimates of -0.20.</li>
<li>The Dallas Fed&#8217;s Texas manufacturing activity index rose to -2.7 in November compared to a reading of -3 in the previous month and versus market estimates of -2.4.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42163921/top-3-real-estate-stocks-that-may-explode-in-q4">Top 3 Real Estate Stocks That May Explode In Q4</a></li>
</ul>

Equities

News

Eurozone

Commodities

Intraday Update

Trading Ideas

BBIO

CMAX

ONCT

QUBT

RGTI

SAVA

Gold Down Over 3%; Rigetti Computing Shares Spike Higher

<a href="https://www.wsj.com/business/media/nbc-ready-to-pay-triple-to-gobble-up-thanksgiving-parade-broadcast-rights-e18fd95f?mod=latest_headlines" title="https://www.wsj.com/business/media/nbc-ready-to-pay-triple-to-gobble-up-thanksgiving-parade-broadcast-rights-e18fd95f?mod=latest_headlines">https://www.wsj.com/business/media/nbc-ready-to-pay-triple-to-gobble-up-thanksgiving-parade-broadcast-rights-e18fd95f?mod=latest_headlines</a>

CMCSA

'NBC, Macy's Near Pact That Would Triple Fees For Broadcasting Thanksgiving Parade; Macy's Parade's Average Annual Fee Would Increase To $60 Million Under New Terms' - WSJ

Whales with a lot of money to spend have taken a noticeably bearish stance on Atlassian.
Looking at options history for Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 42% of the investors opened trades with bullish expectations and 57% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $79,670 and 12, calls, for a total amount of $594,685.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $320.0 for Atlassian, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Atlassian stands at 418.9, with a total volume reaching 4,121.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Atlassian, situated within the strike price corridor from $200.0 to $320.0, throughout the last 30 days.
<h3>Atlassian Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732562141_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEAM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$21.9</td>
<td>$21.2</td>
<td>$21.4</td>
<td>$280.00</td>
<td>$89.8K</td>
<td align="right">639</td>
<td align="right">45</td>
</tr>
<tr>
<td>TEAM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$31.8</td>
<td>$28.9</td>
<td>$31.8</td>
<td>$260.00</td>
<td>$79.5K</td>
<td align="right">239</td>
<td align="right">25</td>
</tr>
<tr>
<td>TEAM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$18.4</td>
<td>$17.6</td>
<td>$18.2</td>
<td>$290.00</td>
<td>$76.4K</td>
<td align="right">458</td>
<td align="right">45</td>
</tr>
<tr>
<td>TEAM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$72.1</td>
<td>$71.0</td>
<td>$71.0</td>
<td>$200.00</td>
<td>$71.0K</td>
<td align="right">563</td>
<td align="right">10</td>
</tr>
<tr>
<td>TEAM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$7.0</td>
<td>$6.5</td>
<td>$7.0</td>
<td>$262.50</td>
<td>$52.5K</td>
<td align="right">0</td>
<td align="right">75</td>
</tr>
</tbody>
</table>

<h3>About Atlassian</h3>
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Following our analysis of the options activities associated with Atlassian, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Atlassian</h3>
<ul>
<li>With a volume of 1,457,643, the price of TEAM is up 0.7% at $262.4. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 66 days.</li>
</ul>
<h3>What Analysts Are Saying About Atlassian</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $253.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Jefferies persists with their Buy rating on Atlassian, maintaining a target price of $300. 
&#x2A; Showing optimism, an analyst from Keybanc upgrades its rating to Overweight with a revised price target of $260. 
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Market Perform rating on Atlassian with a target price of $255. 
&#x2A; Consistent in their evaluation, an analyst from Raymond James keeps a Outperform rating on Atlassian with a target price of $250. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Hold rating on Atlassian with a target price of $200. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Atlassian, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

TEAM

Atlassian's Options: A Look at What the Big Money is Thinking

High-rolling investors have positioned themselves bullish on Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ANET often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 19 options trades for Arista Networks. This is not a typical pattern.
The sentiment among these major traders is split, with 42% bullish and 31% bearish. Among all the options we identified, there was one put, amounting to $25,100, and 18 calls, totaling $1,171,479.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $310.0 to $460.0 for Arista Networks during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Arista Networks's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Arista Networks's whale trades within a strike price range from $310.0 to $460.0 in the last 30 days. 
<h3>Arista Networks Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732562136_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$51.1</td>
<td>$48.2</td>
<td>$49.55</td>
<td>$370.00</td>
<td>$297.3K</td>
<td align="right">110</td>
<td align="right">2</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$19.8</td>
<td>$19.4</td>
<td>$19.8</td>
<td>$390.00</td>
<td>$194.0K</td>
<td align="right">545</td>
<td align="right">126</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$41.2</td>
<td>$39.9</td>
<td>$41.0</td>
<td>$400.00</td>
<td>$82.0K</td>
<td align="right">309</td>
<td align="right">25</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$64.1</td>
<td>$62.7</td>
<td>$63.4</td>
<td>$350.00</td>
<td>$63.4K</td>
<td align="right">295</td>
<td align="right">10</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$35.6</td>
<td>$34.0</td>
<td>$34.0</td>
<td>$400.00</td>
<td>$51.0K</td>
<td align="right">263</td>
<td align="right">21</td>
</tr>
</tbody>
</table>

<h3>About Arista Networks</h3>
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.
After a thorough review of the options trading surrounding Arista Networks, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Arista Networks</h3>
<ul>
<li>Currently trading with a volume of 960,929, the ANET's price is down by -1.93%, now at $398.62. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 77 days.</li>
</ul>
<h3>What Analysts Are Saying About Arista Networks</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $424.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Arista Networks, maintaining a target price of $495. 
&#x2A; Consistent in their evaluation, an analyst from Rosenblatt keeps a Sell rating on Arista Networks with a target price of $320. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Arista Networks, targeting a price of $425. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Arista Networks, maintaining a target price of $460. 
&#x2A; Reflecting concerns, an analyst from Piper Sandler lowers its rating to Neutral with a new price target of $421.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Arista Networks, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ANET

Unpacking the Latest Options Trading Trends in Arista Networks

Deep-pocketed investors have adopted a bearish approach towards Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CMG usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Chipotle Mexican Grill. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 22% leaning bullish and 55% bearish. Among these notable options, 2 are puts, totaling $111,505, and 7 are calls, amounting to $530,228.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $35.2 to $63.0 for Chipotle Mexican Grill over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Chipotle Mexican Grill's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Chipotle Mexican Grill's significant trades, within a strike price range of $35.2 to $63.0, over the past month.
<h3>Chipotle Mexican Grill 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732562131_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$7.2</td>
<td>$7.1</td>
<td>$7.17</td>
<td>$58.00</td>
<td>$182.1K</td>
<td>2.3K</td>
<td align="right">263</td>
</tr>
<tr>
<td>CMG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.4</td>
<td>$6.3</td>
<td>$6.3</td>
<td>$63.00</td>
<td>$81.9K</td>
<td>1.1K</td>
<td align="right">151</td>
</tr>
<tr>
<td>CMG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.45</td>
<td>$1.4</td>
<td>$1.45</td>
<td>$51.00</td>
<td>$73.9K</td>
<td>4.9K</td>
<td align="right">510</td>
</tr>
<tr>
<td>CMG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$18.6</td>
<td>$17.6</td>
<td>$18.1</td>
<td>$55.00</td>
<td>$72.4K</td>
<td>171</td>
<td align="right">40</td>
</tr>
<tr>
<td>CMG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$32.4</td>
<td>$30.1</td>
<td>$30.4</td>
<td>$35.20</td>
<td>$63.8K</td>
<td>37</td>
<td align="right">27</td>
</tr>
</tbody>
</table>

<h3>About Chipotle Mexican Grill</h3>
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $9.9 billion in 2023. The Mexican concept is almost exclusively company-owned, with just two license stores opearted through a master franchise relationship with Alshaya Group in the Middle East. It had a footprint of nearly 3,440 stores at the end of 2023, heavily indexed to the United States, although it maintains a small presence in Canada, the UK, France, and Germany. Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
After a thorough review of the options trading surrounding Chipotle Mexican Grill, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Chipotle Mexican Grill's Current Market Status</h3>
<ul>
<li>With a volume of 6,882,849, the price of CMG is up 0.39% at $62.25. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 71 days.</li>
</ul>
<h3>What The Experts Say On Chipotle Mexican Grill</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $65.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Loop Capital keeps a Hold rating on Chipotle Mexican Grill with a target price of $58. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $70. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Chipotle Mexican Grill, which currently sits at a price target of $70. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Chipotle Mexican Grill, which currently sits at a price target of $68. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for Chipotle Mexican Grill, targeting a price of $60. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Chipotle Mexican Grill options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Check Out What Whales Are Doing With CMG

Editor&#8217;s note: This article has been updated to clarify that the Czech government approved a draft bill regarding cannabis cultivation rather than having legalized marijuana cultivation and possession of 50 grams as was previously reported.
The Czech government recently proposed a draft law that would reform criminal law regarding cannabis, with changes including relaxed rules on home cultivation and possession. The draft law now needs to be viewed by both chambers of Parliament.
 During a press conference, Justice Minister Pavel Blažek spoke about raising and favoring financial penalties over imprisonment for cannabis offenses.
"Our punishment system is outdated and diverging from the rest of the EU, which is obviously not good," Blažek said, <a href="https://www.echo24.cz/a/H5KfB/zpravy-vlada-schvalila-novela-trestniho-zakoniku-ministr-spravedlnosti-pavel-blazek-vezeni-konopi-tresty">reported</a> Echo24, according to translation.
Under the proposed changes, which could take months to be approved, cultivating up to three cannabis plants and possessing up to 50 grams outside the home and 25 grams inside would be legal. Cultivating four to five plants would be treated as a minor offense, but anything more than that would be considered criminal activity.
The opposition Pirate Party argued that the proposal is inadequate because allowing cultivation of several plants does not permit their harvest, as three plants could yield up to 300 grams.
"Instead of legalization and additional revenue for the budget, the government presents a botched proposal," said former Deputy Prime Minister and ex-leader of the Pirate Party Ivan Bartoš. "You can grow cannabis, but you can't harvest it. Allowing the cultivation of three cannabis plants while limiting possession to 50 grams at home is absurd. It's like being allowed to keep three hens, but if they lay more than one egg, you face a fine or jail time."
Bartoš further argued that proposal is complicating the situation for up to 600,000 medical marijuana patients. The Pirate Party plans to propose increasing the legal possession limit to 900 grams.
The government wants to implement the approved changes before the end of its term.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41295350/czech-senate-approves-restrictions-on-sale-of-kratom-and-hhc-products">Czech Senate Approves Restrictions On Sale Of Kratom And HHC Products</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Recent Calls For Regulated Cannabis Market</h2>
The news comes several months after the governing coalition confirmed it supports cannabis cultivation, but not the establishment of a regulated marijuana market. At the same time, former National Drug Coordinator Jindřich Vobořil shared he doesn't believe that the game is over for full legalization and <a href="https://www.benzinga.com/markets/cannabis/24/08/40626067/full-cannabis-legalization-not-yet-off-the-table-in-czech-republic-some-lawmakers-want-only-home" target="_blank" rel="noreferrer noopener">continues to push for it</a>.
Meanwhile, a recent study conducted by the researchers from the Faculty of Business Economics at the University of Prague concluded that the country could be <a href="https://www.benzinga.com/markets/cannabis/24/09/40879273/this-european-country-could-lose-242m-a-year-if-it-doesnt-regulate-its-marijuana-market-study-fi" target="_blank" rel="noreferrer noopener">missing out on hundreds of millions of euros </a>annually if it doesn&#8217;t establish a regulated marijuana market. As per the report a &#8220;comprehensive model,&#8221; incorporating self-cultivation, cannabis clubs and a fully commercial market, could result in "total net social benefits of CZK 5.5 billion (218 million euros; $242 million) per year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41890759/polish-parliamentary-committee-sends-cannabis-decriminalization-petition-to-prime-minister">Polish Parliamentary Committee Sends Cannabis Decriminalization Petition To Prime Minister</a></li>
</ul>
Photo: Courtesy of JESHOOTS.com via Pexels

Cannabis

Czech Government Approves Draft Law That Would Legalize Cultivation Of 3 Cannabis Plants, Possession Of 50 Grams (UPDATED)

The COP29 climate summit in Baku, Azerbaijan, concluded yesterday with an agreement to provide $300 billion annually to developing nations by 2035, helping to mitigate and adapt to the impacts of <a href="https://www.benzinga.com/topic/climate-change">climate change</a>. While hailed as progress to the <a href="https://www.benzinga.com/news/global/24/11/41925800/urgency-debate-mark-cop29-as-leaders-push-for-carbon-market-rules-worry-about-trump">previous $100 billion commitment</a>, the sum fell short of the $1.3 trillion initially identified as necessary to address the crisis.
&#8220;Without more substantial financing, many vulnerable countries will remain underprepared for escalating climate challenges,&#8221;<a href="https://www.wri.org/news/statement-cop29-finance-deal-downpayment-safer-more-equitable-future"> said</a> Ani Dasgupta, CEO of the World Resources Institute.
The agreement has drawn mixed reactions. Per BBC, India<a href="https://www.bbc.com/news/articles/cd0gx4przejo"> criticized</a> the deal as a "paltry sum," while Nigeria labeled it a "joke." Delegates from the Marshall Islands expressed disappointment, describing the funding as woefully inadequate, yet acknowledged it as a starting point.
Meanwhile, wildlife conservation organization WWF expressed concern, calling the deal far below the ambition needed.
"The world has been let down by this weak climate finance deal. This is a serious blow to climate action, but it must not stall the solutions that are desperately needed around the world,"<a href="https://wwf.panda.org/wwf_news/press_releases/?12844466/COP29-outcome"> said</a> WWF Global Climate and Energy Lead and COP20 President Manuel Pulgar-Vidal.
The world remains on track for a temperature rise of 3.1°C by the century&#8217;s end. That&#8217;s far above the Paris Agreement&#8217;s goal of limiting warming to 1.5°C, according to<a href="https://news.un.org/en/story/2024/10/1156071"> recent</a> UN reports.
Under the 1992 UN Framework Convention on Climate Change, 23 developed nations and the European Union must contribute to climate finance. The agreement also encourages private investment and contributions from institutions like the World Bank to meet the funding targets. The funds will support adaptation efforts. That includes building flood-resistant infrastructure and sustainable agriculture and facilitating a transition to renewable energy in developing nations.
Additionally, the summit finalized rules for a global carbon market. This system will allow companies to offset emissions by purchasing credits linked to reforestation and renewable energy initiatives. These efforts aim to accelerate the implementation of Nationally Determined Contributions (NDCs), with countries required to update their climate action plans by February 2025.
President Joe Biden<a href="https://www.whitehouse.gov/briefing-room/statements-releases/2024/11/23/statement-from-president-joe-biden-on-conclusion-of-cop29-conference-in-baku-azerbaijan/"> called</a> the agreement "an essential step toward mobilizing funds to combat the climate crisis" while acknowledging the work ahead. However, President-elect Donald Trump's return raises doubt over the future of U.S. involvement, particularly given his previous withdrawal from the Paris Agreement.
The Brazilian city of Belém will host the next summit, COP30, in November 2025. Brazilian officials have promised a high-stakes event they call the "COP of COPs," focusing on limiting global warming to 1.5°C.
iShares Global  Clean Energy ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLN#NASDAQ">ICLN</a>) rose following the news. At 12:45 pm EST, it was trading 1.83% higher at $12.34.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42170135/its-the-most-wonderful-time-of-the-year-for-the-stock-market-history-says">&#8216;It&#8217;s The Most Wonderful Time Of The Year&#8217; For The Stock Market, History Says</a></li>
</ul>
Image: Shutterstock

Legal

Global

iShares S&P Global Clean Energy Index Fund

ICLN

$300 Billion 'Joke': COP29 Reps Scoff At 'Paltry Sum' For Climate Change

<a href="https://www.wsj.com/livecoverage/stock-market-today-dow-sp500-nasdaq-live-11-25-2024/card/exclusive-starbucks-wrestles-with-ransomware-attack-on-software-supplier-cZJuRHR4rUCg8rOc9LJQ" title="https://www.wsj.com/livecoverage/stock-market-today-dow-sp500-nasdaq-live-11-25-2024/card/exclusive-starbucks-wrestles-with-ransomware-attack-on-software-supplier-cZJuRHR4rUCg8rOc9LJQ">https://www.wsj.com/livecoverage/stock-market-today-dow-sp500-nasdaq-live-11-25-2024/card/exclusive-starbucks-wrestles-with-ransomware-attack-on-software-supplier-cZJuRHR4rUCg8rOc9LJQ</a>

SBUX

Starbucks Wrestles With Ransomware Attack On Software Supplier Blue Yonder, Disrupting Employee Scheduling And Pay Tracking While Ensuring Baristas Receive Full Compensation For Hours Worked

Sony Group Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) is reportedly preparing to introduce black versions of its DualSense Edge controller, Pulse Elite wireless headphones and Pulse Explore <a href="https://www.benzinga.com/general/gaming">wireless earbuds. </a>
The news comes from renowned leaker billbil-kun <a href="https://www.dealabs.com/magazine/ces-accessoires-ps5-sortiront-bientot-dans-un-tout-nouveau-coloris-59696">via</a> Dealabs, who suggested the announcement could arrive in time for PlayStation&#8217;s 30th anniversary celebrations in December.
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/42098642/play-ps5-games-without-a-console-playstation-portal-adds-cloud-streaming">Play PS5 Games Without A Console: PlayStation Portal Adds Cloud Streaming</a>
<h1 class="wp-block-heading">Familiar Prices, Bold New Look</h1>
According to billbil-kun, the black variants will be priced identically to their current white counterparts:
<ul>
<li>DualSense Edge controller: $199.99 / 239.99 euros / 209.99 pounds</li>
<li>Pulse Elite headphones: $149.99 / 149.99 euros / 129.99 pounds</li>
<li>Pulse Explore earbuds: $199.99 / 219.99 euros / 199.99 pounds</li>
</ul>
This consistency in pricing provides a compelling alternative for those who prefer a darker aesthetic without compromising on cost.
<h1 class="wp-block-heading">A Nod To PlayStation's Milestone</h1>
The timing of this rumored release aligns perfectly with Sony&#8217;s <a href="https://www.benzinga.com/general/gaming/24/09/41055245/ps5-30th-anniversary-chaos-scalpers-sweep-up-stock-leaving-fans-empty-handed">ongoing 30th-anniversary celebrations</a>, which have already included the unveiling of limited-edition PS5 consoles. A potential announcement on Dec. 3, the official anniversary date, could add to the festivities.
PlayStation has historically celebrated its milestones with special product launches, and these black accessories would continue that tradition. They also mark a shift from the white-dominated palette introduced with the PS5, giving fans more personalization options for their gaming setups.
In related news, Sony is said to be in the early stages of developing a <a href="https://www.benzinga.com/24/11/42161830/sony-eyes-portable-gaming-market-with-new-handheld-console-in-development">portable PlayStation 5.</a> 
This development aligns with the growing trend of portable gaming, spurred by competitors like the Nintendo Switch and Steam Deck.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/42169267/how-baldurs-gate-3-turned-larian-studios-into-a-447-million-powerhouse">How Baldur&#8217;s Gate 3 Turned Larian Studios Into A $447 Million Powerhouse</a></li>
</ul>

Gaming

General

Sony Group Corporation American Depositary Shares

SONY

Black PlayStation Accessories May Appear Ahead Of Holiday Season: Dealabs

<a href="https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_11252024_IMNN_Bautz.pdf" title="https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_11252024_IMNN_Bautz.pdf">https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_11252024_IMNN_Bautz.pdf</a>

Analyst Ratings

IMNN

Watching Imunon; Zacks Small-Cap Research Gives Stock $8 Price Valuation

AISP

ALAB

AMBA

ARQQ

ATOM

CFLT

CSIQ

DIOD

DOCU

ENPH

FSLR

INDI

LAES

LPSN

LSCC

MANH

MCHP

MNDY

MPWR

NICE

NTRP

NVTS

NXPI

PCOR

POWI

RDZN

SEDG

SLAB

SMSI

SWKS

SYNA

UPLD

WKEY

WOLF

ZENA

Shares of semiconductor and software stocks are trading higher, with stocks broadly rising amid a drop in yields. President-elect Trump nominated Scott Bessent as Treasury Secretary.

<a href="https://x.com/Zevia/status/1861122204433252406" title="https://x.com/Zevia/status/1861122204433252406">https://x.com/Zevia/status/1861122204433252406</a>

ZVIA

Watching Shares Of Zevia; Company Posts On X, "Find us at @walmart NATIONWIDE with 10 naturally delicious flavors, plus our exclusive Walmart new Variety 8 Pack!"

<a href="https://www.theglobeandmail.com/business/industry-news/energy-and-resources/article-cleveland-cliffs-ceo-still-keen-on-acquiring-us-steel-as-uncertainty/" title="https://www.theglobeandmail.com/business/industry-news/energy-and-resources/article-cleveland-cliffs-ceo-still-keen-on-acquiring-us-steel-as-uncertainty/">https://www.theglobeandmail.com/business/industry-news/energy-and-resources/article-cleveland-cliffs-ceo-still-keen-on-acquiring-us-steel-as-uncertainty/</a>

'Cleveland-Cliffs CEO still keen on acquiring U.S. Steel as uncertainty weighs on Nippon bid' - The Globe And Mail

Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $50.73, a high estimate of $60.00, and a low estimate of $41.00. Witnessing a positive shift, the current average has risen by 6.29% from the previous average price target of $47.73.
<img src="https://www.benzinga.com/files/images/story/2024/1732561279_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Summit Materials by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrian Heurta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.50</td>
<td>$43.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$52.50</td>
<td>$54.00</td>
</tr>
<tr>
<td>Brent Thielman</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Garik Shmois</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Adam Seiden</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Brent Thielman</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Philip Ng</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$56.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$46.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Adrian Heurta</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$47.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Summit Materials. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Summit Materials compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Summit Materials's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Summit Materials's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SUM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Summit Materials analyst ratings.</a>
<h2>Discovering Summit Materials: A Closer Look</h2>
Summit Materials Inc is engaged in the production and sale of aggregates, cement, ready-mix concrete, asphalt paving mix and concrete products and owns and operates quarries, sand and gravel pits, two cement plants, cement distribution terminals, ready-mix concrete plants, asphalt plants and landfill sites. It is also engaged in paving and related services. The Company's three operating and reporting segments are the West, East and Cement segments. It operates in 21 U.S. states and in British Columbia, Canada and has assets in 21 U.S. states and in British Columbia, Canada through its platform.
<h3>Key Indicators: Summit Materials's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Summit Materials's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 47.35% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 8.98%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Summit Materials's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.4%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Summit Materials's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.26%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Summit Materials's debt-to-equity ratio stands notably higher than the industry average, reaching 0.65. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Summit Materials Stock: Analyst Perspectives (11 Ratings)

Throughout the last three months, 27 analysts have evaluated Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $245.7, a high estimate of $300.00, and a low estimate of $184.00. This upward trend is evident, with the current average reflecting a 1.34% increase from the previous average price target of $242.46.
<img src="https://www.benzinga.com/files/images/story/2024/1732561266_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Apple is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erik Woodring</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$273.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Tom Forte</td>
<td>Maxim Group</td>
<td>Raises</td>
<td>Hold</td>
<td>$215.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$184.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$262.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Brandon Nispel</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Underweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Kyle Mcnealy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$212.92</td>
<td>$205.00</td>
</tr>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$256.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$186.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Pierre Ferragu</td>
<td>New Street Research</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Martin Yang</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$256.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Tom Forte</td>
<td>Maxim Group</td>
<td>Maintains</td>
<td>Hold</td>
<td>$203.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$261.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Erik Woodring</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$273.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$256.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>David Vogt</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$236.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$295.00</td>
<td>$245.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Apple. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Apple compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Apple's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Apple's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AAPL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Apple analyst ratings.</a>
<h2>All You Need to Know About Apple</h2>
Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.
<h3>Key Indicators: Apple's Financial Health</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Apple's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.07% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 15.52%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Apple's ROE excels beyond industry benchmarks, reaching 23.83%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Apple's ROA stands out, surpassing industry averages. With an impressive ROA of 4.23%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Apple's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.87, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPL

What 27 Analyst Ratings Have To Say About Apple

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday!



Moving stocks this morning are earnings reports, a dividend, shareholder meeting results and more.



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>MBIA (NYSE:<a href="https://investorplace.com/stock-quotes/mbi-stock-quote/">MBI</a>) stock is rocketing more than 58% after <a href="https://finance.yahoo.com/news/mbia-inc-declares-extraordinary-cash-213700040.html">declaring a special cash dividend</a>.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) shares are soaring over 55% alongside heavy pre-market trading.</li>



<li>FLJ (NASDAQ:<a href="https://investorplace.com/stock-quotes/flj-stock-quote/">FLJ</a>) stock is surging close to 45% with strong early morning trading.</li>



<li>Torrid (NYSE:<a href="https://investorplace.com/stock-quotes/curv-stock-quote/">CURV</a>) shares are gaining more than 16% after releasing its <a href="https://www.nasdaq.com/press-release/torrid-reports-third-quarter-fiscal-2023-results-2023-12-07">Q3 earnings report</a>.</li>



<li>Meta Materials (NASDAQ:<a href="https://investorplace.com/stock-quotes/mmat-stock-quote/">MMAT</a>) stock is increasing over 13% as it <a href="https://investorplace.com/2023/12/mmat-stock-meta-materials-speaks-out-on-reverse-stock-split-proposal/">seeks a reverse stock split</a>.</li>



<li>Micromobility.com (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcom-stock-quote/">MCOM</a>) shares are climbing more than 13% without any clear news.</li>



<li>Biolase (NASDAQ:<a href="https://investorplace.com/stock-quotes/biol-stock-quote/">BIOL</a>) stock is heading over 12% higher after <a href="https://www.nasdaq.com/press-release/biolase-inc.-announces-pricing-of-%241.4-million-registered-direct-offering-priced-at">pricing an offering yesterday</a>.</li>



<li>Estrella Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/">ESLA</a>) shares are rising more than 12% this morning.</li>



<li>Root (NASDAQ:<a href="https://investorplace.com/stock-quotes/root-stock-quote/">ROOT</a>) stock is jumping over 11% without any obvious news on Friday.</li>



<li>Virax Biolabs (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrax-stock-quote/">VRAX</a>) shares are up more than 11% alongside <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317915935&amp;type=PDF&amp;symbol=VRAX&amp;cdn=b06fb6b886b911f8cbc436f2eecb3a52&amp;companyName=Virax+Biolabs+Group+Limited&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2023-12-08">shareholder meeting results</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Cyngn (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyn-stock-quote/">CYN</a>) stock is plummeting over 36% following <a href="https://investorplace.com/2023/12/why-is-cyngn-cyn-stock-up-73-today/">a major rally yesterday</a>.</li>



<li>Golden Heaven (NASDAQ:<a href="https://investorplace.com/stock-quotes/gdhg-stock-quote/">GDHG</a>) shares are diving more than 23% as it continues a recent fall.</li>



<li>HashiCorp (NASDAQ:<a href="https://investorplace.com/stock-quotes/hcp-stock-quote/">HCP</a>) stock is tumbling over 23% with its <a href="https://finance.yahoo.com/news/hashicorp-announces-third-quarter-fiscal-210500073.html">latest earnings release</a>.</li>



<li>Hempacco (NASDAQ:<a href="https://investorplace.com/stock-quotes/hpco-stock-quote/">HPCO</a>) shares are taking a more than 21% beating <a href="https://investorplace.com/2023/12/why-is-hempacco-hpco-stock-up-56-today/">after a rally yesterday</a>.</li>



<li>Troika Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/trka-stock-quote/">TRKA</a>) stock is sliding over 19% after <a href="https://investorplace.com/2023/12/why-is-troika-media-group-trka-stock-down-77-today/">filing for bankruptcy</a>.</li>



<li>Avid Bioservices (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdmo-stock-quote/">CDMO</a>) shares are decreasing more than 19% after <a href="https://finance.yahoo.com/news/avid-bioservices-cdmo-reports-q2-224002715.html">releasing lackluster earnings</a>.</li>



<li>China Liberal Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/cleu-stock-quote/">CLEU</a>) stock is falling over 18% after rallying yesterday.</li>



<li>Save Foods (NASDAQ:<a href="https://investorplace.com/stock-quotes/svfd-stock-quote/">SVFD</a>) shares are slipping more than 15% after <a href="https://www.marketwatch.com/story/save-foods-shares-more-than-double-on-nitrousink-deal-9bde44aa">rallying Thursday on a deal</a>.</li>



<li>Greenbrook TMS (NASDAQ:<a href="https://investorplace.com/stock-quotes/gbnh-stock-quote/">GBNH</a>) stock is dipping over 13% today.</li>



<li>Parts ID (NYSEMKT:<a href="https://investorplace.com/stock-quotes/id-stock-quote/">ID</a>) shares close out our pre-market stock movers down more than 12%.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-dec-8th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We&rsquo;re starting out the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!



Moving stocks are investments, acquisitions, new agreements and more.



Let&rsquo;s get into that news down



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is rocketing more than 71% with heavy trading on Empery Asset Management, LP <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317981363&amp;type=PDF&amp;symbol=VLCN&amp;cdn=0a561d788a48501f1c170c0f63b65ac5&amp;companyName=Volcon+Inc.&amp;formType=SC+13G%2FA&amp;formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-01-11">taking a stake in the company</a>.</li>



<li>Charge Enterprises (NASDAQ:<a href="https://investorplace.com/stock-quotes/crge-stock-quote/">CRGE</a>) shares are soaring over 41% with strong early morning trading.</li>



<li>Aeries Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/aert-stock-quote/">AERT</a>) stock is surging more than 35% alongside heavy trading this morning.</li>



<li>Jet AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/jtai-stock-quote/">JTAI</a>) shares are increasing over 20% as it also sees strong trading on Friday morning.</li>



<li>Aileron Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/alrn-stock-quote/">ALRN</a>) stock is gaining more than 18% following its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317981539&amp;type=PDF&amp;symbol=ALRN&amp;cdn=2219d39279c110c1197b97762ea29d5d&amp;companyName=Aileron+Therapeutics+Inc.&amp;formType=8-K%2FA&amp;formDescription=%5BAmend%5DCurrent+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-01-11">acquisition of Lung Therapeutics</a>.</li>



<li>Hyperfine (NASDAQ:<a href="https://investorplace.com/stock-quotes/hypr-stock-quote/">HYPR</a>) shares are heading over 16% higher without any clear news this morning.</li>



<li>Akso Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/ahg-stock-quote/">AHG</a>) stock is climbing more than 14% today.</li>



<li>Emcore (NASDAQ:<a href="https://investorplace.com/stock-quotes/emkr-stock-quote/">EMKR</a>) shares are jumping over 13% with a <a href="https://www.nasdaq.com/press-release/emcore-corporation-enters-into-cooperation-agreement-with-bradley-l.-radoff-2024-01">new cooperation agreement</a>.</li>



<li>Apollomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/aplm-stock-quote/">APLM</a>) stock is rising more than 13% this morning.</li>



<li>Safe &amp; Green Development (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgd-stock-quote/">SGD</a>) shares are up over 13% on Friday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Estrella Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/">ESLA</a>) stock is crashing more than 46% without any obvious news.</li>



<li>Genius (NYSEMKT:<a href="https://investorplace.com/stock-quotes/gns-stock-quote/">GNS</a>) shares are plummeting over 34% after <a href="https://www.nasdaq.com/press-release/genius-group-announces-pricing-of-%248.25-million-public-offering-2024-01-12">pricing a public offering</a>.</li>



<li>VCI Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcig-stock-quote/">VCIG</a>) stock is diving more than 27% with <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317975438&amp;type=PDF&amp;symbol=VCIG&amp;cdn=d1e913c93adb43c9620f5e05d59906d8&amp;companyName=VCI+Global+Limited&amp;formType=F-1%2FA&amp;formDescription=%5BAmend%5D+Registration+statement+for+certain+foreign+private+issuers&amp;dateFiled=2024-01-08">a public offering</a>.</li>



<li>SealSQ (NASDAQ:<a href="https://investorplace.com/stock-quotes/laes-stock-quote/">LAES</a>) shares are taking an over 20% beating <a href="https://www.globenewswire.com/news-release/2024/01/10/2807169/0/en/SEALSQ-Announces-FY-2023-Preliminary-Unaudited-Revenue-of-30-Million-Marking-a-29-Increase-Over-FY-2022.html">alongside preliminary earnings</a>.</li>



<li>Future FinTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/ftft-stock-quote/">FTFT</a>) stock is tumbling more than 13% following <a href="https://www.marketwatch.com/story/future-fintech-stock-drops-13-after-sec-charges-ceo-68d81977">charges against its CEO</a>.</li>



<li>Vivopower (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvpr-stock-quote/">VVPR</a>) shares are sliding over 12% after its <a href="https://www.marketwatch.com/story/vivopower-international-shares-rise-after-subsidiary-tembo-meets-milestones-for-strategic-direct-equity-investment-05502abe">subsidiary met certain milestones</a>.</li>



<li>Tarena International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) stock is decreasing more than 11% this morning.</li>



<li>MAIA Biotechnology (NYSEMKT:<a href="https://investorplace.com/stock-quotes/maia-stock-quote/">MAIA</a>) shares are dropping over 11% on Friday.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) stock is falling more than 9% without any news to report.</li>



<li>Eightco (NASDAQ:<a href="https://investorplace.com/stock-quotes/octo-stock-quote/">OCTO</a>) shares close out our pre-market stock movers down close to 9%.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT766529">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/01/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-jan-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession, the U.S. has shown resilience and strong growth since interest rates started going up in March 2022. This suggests a positive outlook for the U.S. economy in the coming months. With our economy, looking to perform well this year you need to invest in these <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> that will provide high returns this year, with their new advances.



<h2>Catalyst Pharmaceuticals (CPRX)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/pill-bottle-biopharma-biotech-1600-300x169.jpg" alt="Brown glass pill bottle on its side showing white pills inside, with other pill bottles behind it representing MACK stock."><div>Source: shutterstock.com/Champhei</div></div>


Catalyst Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cprx-stock-quote/">CPRX</a>) is a pharmaceutical company that focuses on licensing the rights to the cures of rare diseases. It has a valuation of $<a href="https://www.google.com/finance/quote/CPRX:NASDAQ?sa=X&amp;ved=2ahUKEwj0wbXG-uKDAxV1FVkFHUAxAX8Q3ecFegQIDhAX">14.36</a>, with a YoY decrease of <a href="https://www.google.com/finance/quote/CPRX:NASDAQ?sa=X&amp;ved=2ahUKEwj0wbXG-uKDAxV1FVkFHUAxAX8Q3ecFegQIDhAX&amp;window=1Y">28.70%</a>. However, it appears to be poised for growth.



Although Catalyst has consistently <a href="https://finance.yahoo.com/quote/CPRX?p=CPRX">missed earnings estimates</a> by small margins, 4 Yahoo Finance! investors have given it a <a href="https://finance.yahoo.com/quote/CPRX?p=CPRX">buy rating</a>. Additionally, 5 analysts have given it a price target of <a href="https://finance.yahoo.com/quote/CPRX?p=CPRX">$26.20</a>, far above its current valuation. It has a debt of $3.64 million, with a free cash flow of $120.97 million. This gives it plenty of liquid assets to invest in the development of new drugs.



A few key drugs Catalyst has in its pipeline include drugs for <a href="https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-reports-fda-approval-agamreer">Duchenne muscular dystrophy</a>. This disease will have a market of <a href="https://www.alliedmarketresearch.com/duchenne-muscular-dystrophy-market-A15646">$2.07 billion in 2031</a>, with a CAGR of 4.7%. This is much more than Catalyst&rsquo;s current market cap of <a href="https://finance.yahoo.com/quote/CPRX/key-statistics?p=CPRX">$1.69 billion</a>, showing potential for future growth. Additionally, sales for current drugs are expected to hold steady. This makes it one of those biotech stocks to consider.



Management is expected to continue buying the rights to and developing drugs for niche, in-demand disorders. This opens the possibility of future growth. Coupled with being perceived as undervalued at the moment, it becomes clear why Catalyst Pharmaceuticals is a stock you should invest in.



<h2>Estrella Immunopharma (ESLA)&nbsp;</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/pharmaceutical1600-300x169.png" alt="pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory"><div>Source: Dmitry Kalinovsky / Shutterstock.com</div></div>


Estrella Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/">ESLA</a>) is an American biopharmaceutical company focusing on the development of T-cell therapies. Headquartered in Emeryville, CA, ESLA has amassed a valuation of <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$1.03</a>.&nbsp;



Developing innovative therapies for solid tumors using novel &ldquo;mark-and-kill&rdquo; methods, ESLA has amassed a valuation of <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$62.67</a> &mdash; down 14.17% in the past month.



Valued at <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$36.26 millio</a>n, the biopharmaceuticals market size is estimated at $516.79 billion in 2024 and is expected to reach $761.80 billion by 2029, growing at a <a href="https://www.mordorintelligence.com/industry-reports/global-biopharmaceuticals-market-industry">CAGR </a>of 8.07% during the forecast period.



Financially, ESLA improved on almost every metric during Q3 2023. ESLA reported <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">$-1.87 million</a> in net income, a YoY increase of <a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX">35.17%</a>. Total assets also received a massive surge of $27.35 million increasing over<a href="https://www.google.com/finance/quote/ESLA:NASDAQ?sa=X&amp;ved=2ahUKEwiJ_8zs29ODAxUxkokEHVK2B3kQ3ecFegQIIBAX"> 750%</a> YoY. Overall, Q3 &lsquo;23 proved to be successful for ESLA, with the company outperforming previous years on net change in cash, increasing 1,886.80% YoY. This increase in liquidity makes it one of those biotech stocks for investors to pay close attention to.



ESLA is set up for success through recent <a href="https://www.estrellabio.com/pipeline">research</a> in novel drugs and therapies. It is developing advanced T-cell therapies, particularly focusing on its CD19-Redirected ARTEMIS T Cells. This approach is being applied initially to high-risk blood cancers. As ESLA continues to include an emphasis on research and development, expect ESLA valuation to climb as more customers gravitate towards the company&rsquo;s products.



<h2>VolitionRX (VNRX)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>


VolitionRX (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/vnrx-stock-quote/">VNRX</a>) is a biotech company that takes part in the creation of blood-based cancer tests, helping diagnose a range of cancers. The company is based in Henderson, NV, and has amassed a valuation of <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">$0.86</a> with a strong increase of <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">48.88%</a> in just the last month.&nbsp;&nbsp;



VNRX is fully established in the market but still shows signs of future growth. Valued at <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">$67.94 million</a> in 2023, The global biotechnology market size accounted for $368 Billion in 2021 and is anticipated to reach $1,334 Billion by 2030 with a <a href="https://www.linkedin.com/pulse/biotechnology-market-anticipated-reach-usd-1334-billion/">CAGR </a>of 15.5%. 



Financially, VNRX improved on almost every metric during Q3 2023. VNRX reported <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">$165.21K</a> in revenue, a YoY increase of <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">405.02%</a>. Net profit margin also received massive surges of $-5.07K, increasing over <a href="https://www.google.com/finance/quote/VNRX:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwiWy4bh2NODAxX7jIkEHRJGDCIQ3ecFegQIIhAX">70%</a> YoY. Overall, Q3 &lsquo;23 proved to be successful for VNRX, with the company YoY outperforming EPS by 23.64%.&nbsp;



VNRX is set up for success through recent<a href="https://finance.yahoo.com/news/volition-vpg-launch-nu-q-112400172.html"> announcements</a> of closing on an aggregate of $5.5 m<a href="https://finance.yahoo.com/news/volitionrx-secures-approximately-5-5-130000482.html">illion</a> in financing from investors at Wallonie Entreprendre in Belgium. It has also recently partnered with leading laboratories in the UK and Ireland to launch a groundbreaking cancer test for the early detection and monitoring of cancer in dogs. As VNRX continues to include an emphasis on innovation, expect VNRX valuation to climb as more investors and clients gravitate towards the company&rsquo;s services.



On the date of publication, Michael Que did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.



The researchers contributing to this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Michael Que is a financial writer with extensive experience in the technology industry, with his work featured on Seeking Alpha, Benzinga and MSN Money. He is the owner of Que Capital, a research firm that combines fundamental analysis with ESG factors to pick the best sustainable long-term investments.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/01/next-big-thing-3-biotech-stocks-to-watch-for-groundbreaking-advances/">Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances

Estrella Immunopharma (ESLA) has shared an update. Estrella Immunopharma, Inc. has recently updated their investor presentation on their website, w...

Estrella Immunopharma Unveils Updated Investor Presentation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Estrella Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/">ESLA</a>) just reported results for the third quarter of 2024.<ul><li>Estrella Immunopharma reported earnings per share of -1 cent.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/esla-stock-earnings-estrella-immunopharma-for-q3-of-2024/">ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday morning!



Moving stocks this morning are earnings reports, a failed merger deal, delisting updates and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>VSee Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsee-stock-quote/">VSEE</a>) stock is rocketing more than 159% as the robot maker <a href="https://www.nasdaq.com/press-release/vsee-health-and-ava-robotics-partner-develop-telepresence-solutions-hospital">plans for telepresence solutions</a> for the inpatient intensive care market.</li>



<li>Adagio Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/adgm-stock-quote/">ADGM</a>) shares are soaring close to 36% following its <a href="https://www.businesswire.com/news/home/20240731222906/en/Adagio-Medical-Announces-the-Closing-of-the-Business-Combination-with-ARYA-IV-Creating-a-Publicly-Traded-Company-Focused-on-the-Innovative-Technologies-for-Treatment-of-Cardiac-Arrhythmias">recent public debut</a>.</li>



<li>Akanda (NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock is surging over 35% alongside heavy pre-market trading.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) shares are gaining more than 29% on a <a href="https://www.businesswire.com/news/home/20240801299565/en/Exicure-Inc.-Receives-Positive-Listing-Determination-from-Nasdaq">positive listing update</a> from the Nasdaq Capital Market.</li>



<li>Australian Oilseeds (NASDAQ:<a href="https://investorplace.com/stock-quotes/coot-stock-quote/">COOT</a>) stock is rising 25% after announcing a <a href="https://www.nasdaq.com/press-release/australian-oilseeds-announces-appointment-new-independent-auditor-2024-08-01">new independent auditor</a>.</li>



<li>Tandem Diabetes Care (NASDAQ:<a href="https://investorplace.com/stock-quotes/tndm-stock-quote/">TNDM</a>) shares are increasing nearly 25% with the release of its <a href="https://www.nasdaq.com/press-release/tandem-diabetes-care-announces-second-quarter-2024-financial-results-and-increases">Q2 earnings report</a>.</li>



<li>Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) stock is heading over 23% higher with <a href="https://www.nasdaq.com/press-release/vaccinex-reports-positive-data-signal-ad-phase-1b-2-trial-pepinemab-alzheimers">recent clinical trial news</a>.</li>



<li>AGBA Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/agba-stock-quote/">AGBA</a>) shares are climbing more than 13% without any clear news this morning.</li>



<li>Venus Concept (NASDAQ:<a href="https://investorplace.com/stock-quotes/vero-stock-quote/">VERO</a>) stock is jumping over 13% on Friday morning.</li>



<li>Integral Ad Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/ias-stock-quote/">IAS</a>) shares are up 13% with its <a href="https://www.nasdaq.com/press-release/ias-reports-second-quarter-2024-financial-results-2024-08-01">latest earnings news</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Gamer Pakistan (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/">GPAK</a>) stock is plummeting almost 47% <a href="https://www.pr.com/press-release/917157#:~:text=(Nasdaq%3AGPAK)%20(GPAK,and%20that%20trading%20of%20the">alongside a delisting notice</a>.</li>



<li>Fresh Vine Wine (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vine-stock-quote/">VINE</a>) shares are diving more than 37% with the <a href="https://www.nasdaq.com/press-release/fresh-vine-wine-inc-and-notes-live-inc-mutually-agree-terminate-merger-agreement-2024">termination of a merger agreement</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) stock is tumbling over 30% as Badcock Home Furniture &amp; More <a href="https://nypost.com/2024/08/01/business/major-furniture-chain-badcock-to-shut-all-its-stores-after-120-years/">shuts down all of its stores</a>.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) shares are taking a more than 24% beating on plans for a <a href="https://www.stocktitan.net/news/GNLN/greenlane-announces-board-s-approval-of-reverse-stock-split-9yehmvs5r4ed.html">reverse stock split</a>.</li>



<li>Procore Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/pcor-stock-quote/">PCOR</a>) stock is dropping 22% alongside its <a href="https://www.nasdaq.com/press-release/procore-announces-second-quarter-2024-financial-results-2024-08-01">Q2 earnings report</a>.</li>



<li>Estrella Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/">ESLA</a>) shares are sliding close to 21% on Friday morning.</li>



<li>Intel (NASDAQ:<a href="https://investorplace.com/stock-quotes/intc-stock-quote/">INTC</a>) stock is falling over 20% after releasing its <a href="https://www.theverge.com/2024/8/1/24210656/intel-is-laying-off-over-10000-employees-and-will-cut-10-billion-in-costs">Q2 earnings report</a>.</li>



<li>Smith Micro Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/smsi-stock-quote/">SMSI</a>) shares are decreasing more than 19% with its <a href="https://seekingalpha.com/article/4709513-smith-micro-software-inc-smsi-q2-2024-earnings-call-transcript">latest earnings report</a>.</li>



<li>GraniteShares 2x Long AMZN Daily ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzz-stock-quote/">AMZZ</a>) stock is slipping over 17%.</li>



<li>Snap (NYSE:<a href="https://investorplace.com/stock-quotes/snap-stock-quote/">SNAP</a>) shares close out our pre-market stock movers down more than 17% <a href="https://www.cnbc.com/2024/08/01/snap-shares-plunge-over-20percent-af.html">on weak guidance</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-aug-2nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The latest announcement is out from Estrella Immunopharma (ESLA). Estrella Immunopharma, Inc. has appointed Ms. Hong Zhang as the new Chairperson a...

Estrella Immunopharma Welcomes New Chairperson, Expands Board

Estrella Immunopharma ( ($ESLA) ) just unveiled an update. Estrella Immunopharma, Inc. has appointed Dr. Cheng Liu as Director, President, and CEO ...

Estrella Immunopharma Appoints Dr. Cheng Liu as CEO

ADGM

AERT

AGBA

AKAN

ALRN

AMZZ

APLM

BIOL

CDMO

CLEU

CONN

COOT

CPRX

CRGE

CURV

EMKR

ESLA

FTFT

GBNH

GDHG

GNLN

GPAK

HYPR

INTC

JTAI

MAIA

MCOM

MMAT

OCTO

ROOT

SNAP

SVFD

TCTM

TNDM

TRKA

VCIG

VCNX

VERO

VINE

VLCN

VNRX

VRAX

VSEE

VVPR

XCUR

Small Cap

Opinion

Press Releases

Thinking about buying stock in Estrella Immunopharma, Novo Nordisk, C4 Therapeutics, Plug Power, or LQR House?

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Comments

Estrella Immunopharma

Estrella Immunopharma (ESLA) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO